Local weather conditions, access to cities can impact prevalence of tuberculosis, study finds
Tuberculosis (TB) mostly affects the lungs and can be deadly if untreated. The disease -- symptoms of which include persistent cough, chest pain and fever -- spreads through the air when an infected person coughs or sneezes.
Study highlights
Focusing on 14 nations, including Nigeria and Mozambique, the team, including researchers from Curtin University and The Kids Research Institute Australia, analysed prevalence of tuberculosis from 50 population-based surveys, involving over 15 lakh people.
The researchers estimated how common the disease is at a local level, breaking each country down into grids, each five square kilometres in area, to identify hotspots. "Here we estimate 1.28 million TB cases across 14 countries, with marked spatial variations," the authors wrote in the study published in the journal Communications Medicine.
"Factors such as temperature, precipitation, and access to cities are positively associated with higher TB prevalence, while higher altitude is linked to lower TB prevalence," they wrote.
For example, rainfall tends to keep one spends indoors, thereby increasing person-to-person contact, crowding, and affecting ventilation levels -- all of which have been linked to spreading of tuberculosis, the researchers explained.
Lead researcher Alemneh Liyew, PhD candidate from Curtin University's school of population health, said the study uncovered dramatic differences in disease burden between local regions within countries -- which could prove vital in reducing the impact of tuberculosis.
"This study highlights how factors such as higher temperatures, rainfall, altitude and better access to cities can influence the prevalence of tuberculosis.
Possibilities of expansion
"With this data, health resources can be better targeted towards the communities that need them most," Liyew said. The study is also the first to provide local-level tuberculosis maps across Africa, the researcher said. "Until now, we haven't been able to see where within countries the disease is most concentrated," Liyew said.
Author Kefyalew Alene, associate professor Curtin University, said the study's findings could potentially help fight the disease outside of Africa."While some aspects of the study are Africa-specific, using mapping to identify patterns associated with tuberculosis could help battle the disease in a more targeted manner elsewhere," Alene said.
"One-size-fits-all national strategies aren't as effective, particularly in regions where resources are limited," the researcher said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
21 minutes ago
- NDTV
Breakthrough In Male Birth Control As Hormone-Free Pill Passes Human Safety Test
Researchers have been working on experimental hormone-free male birth control pills, with its first safety test in humans just passed in a breakthrough. The latest results from the early phase 1 clinical trial were published on Tuesday in Communications Medicine. The daily pill, called YCT-529, works by blocking a vitamin A metabolite from binding to its receptor in the testes. It prevents sperm production without affecting hormone levels, the study revealed. The phase 1 clinical trial was conducted on 16 healthy men who had undergone vasectomies. The results showed that the drug was well-tolerated with no serious adverse events reported. The optimal dosage is expected to be around 180 mg, based on the trial results. However, further studies will determine the exact dosage. The trial did not assess the pill's efficacy in reducing sperm and preventing pregnancy, with the medicine developer, YourChoice Therapeutics, running trials to collect that data. However, Dr Stephanie Page, an endocrinologist at the University of Washington School of Medicine, who wasn't involved in the study, said that the safety finding is a crucial milestone. "We really need more reversible contraceptive methods for men," Page said as quoted by Scientific American. Animal studies have shown that fertility returns within 4-6 weeks after stopping the drug in mice and 10-15 weeks in non-human primates. The pill would provide a safe, reversible and non-hormonal alternative to current male birth control methods, such as condoms and vasectomies. "A safe and effective male pill will provide more options to couples for birth control," Gunda Georg, who is a professor in the University of Minnesota College of Pharmacy, said in a statement. The drug molecule was developed there. "It will allow a more equitable sharing of responsibility for family planning and provide reproductive autonomy for men." The pill is currently in phase 2 clinical trials. It may take several years to become available on the market, if it gets approval. Other options in development include NES/T, a hormonal gel, and ADAM, a hydrogel implant that acts as a reversible vasectomy. "The positive results from this first clinical trial laid the groundwork for a second trial, where men receive YCT-529 for 28 days and 90 days, to study safety and changes in sperm parameters," the study authors wrote in their paper.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Natco Pharma to acquire 35.75% stake in Adcock Ingram for ₹2,000 cr
The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals Sanket Koul New Delhi In a bid to enter the African market, Natco Pharma on Wednesday announced that it has submitted a firm intention for a ZAR 4 billion (Rs 2,000 crore) cash offer to acquire a minority stake in South Africa-based drugmaker Adcock Ingram Holdings (AIHL). If approved, the Hyderabad-based company will hold a 35.75 per cent stake in Adcock Ingram by offering ZAR 75.00 ($4.271) per share to minority stakeholders. The deal gives Natco a gateway into South Africa, with AIHL holding a 10 per cent share of the private pharmaceutical market in the country. It is also the largest supplier of hospital and critical care products in South Africa. This transaction would consolidate Natco's existing 0.80 per cent stake, making it the second-largest shareholder in AIHL, behind the Bidvest Group, which holds the remaining 64.25 per cent. 'Post-transaction, Natco will consolidate 35.75 per cent of AIHL's net profits in Natco's financial results in accordance with its shareholding,' the company said in a regulatory filing. If the deal proceeds, Adcock Ingram will be delisted from the Johannesburg Stock Exchange (JSE) and will continue to operate as a private South African business. Rajeev Nannapaneni, chief executive officer and vice-chairman of Natco Pharma, said the proposed acquisition would help the company tap into new revenue streams and expand its presence in one of the largest and fastest-growing emerging markets. In return, AIHL is expected to leverage Natco's research and development capabilities, regulatory expertise, and global marketing network to support local leadership and expansion into new markets. 'AIHL will benefit from a partnership with a research-focused, innovative, and vertically integrated pharmaceutical company, and over time, South Africans will be beneficiaries of wider access to affordable medicines,' said Andrew Hall, chief executive officer, AIHL. Valued at an estimated ZAR 11 billion ($632 million), AIHL generated revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Founded in 1890, the company operates across four segments—prescription, consumer, over-the-counter (OTC), and hospitals. It has a diverse product portfolio ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. The announcement was made after market hours. On Wednesday, Natco Pharma's shares rose by 2.01 per cent, ending the day's trade at Rs 1,034.75 apiece on the Bombay Stock Exchange (BSE).
Hans India
2 days ago
- Hans India
Rise of Tier-2 cities in India's life sciences GCC playbook
By 2030, GCCs in healthcare, life sciences sectors will increase to 160 centres from 100 now India's Global Capability Centers (GCCs) have steadily evolved from cost-saving outposts to critical infrastructure in the global healthcare value chain. Nowhere is this transformation more evident than in the life sciences and healthcare (LSHC) sector - where digital health, regulatory services, and AI-enabled analytics are increasingly being delivered not just from India's metros, but from cities once considered peripheral to the innovation map. Tier-2 cities are not merely absorbing overflow. They are actively stepping into the spotlight. Today, India hosts over 100 LSHC GCCs, employing more than 280,000 professionals. By 2030, that number is expected to reach 160 centers and over 420,000 employees. The shift underway is not just quantitative. It is geographic. And strategic as well. 'Tier-2 cities are emerging as ideal candidates for housing next-generation LSHC GCCs,' Ritu Baliya, Associate Director – Strategy, Healthark Insights, told The Hans India. 'Strong policy support, sector-specific academic pipelines, and improving infrastructure are enabling global enterprises to expand with confidence - not just at lower cost, but with greater long-term alignment'. Ritu Baliya, with over 10 years of experience, has been advising life sciences and healthcare clients worldwide on strategy and market insights. She also supports the growth of Global Capability Centers by helping organizations tap into India's evolving innovation and talent ecosystem. From Kochi to Warangal, Vadodara to Coimbatore, a new network of cities is rewriting the operational map for life sciences capability. These urban centers are now offering what once only metros could: talent continuity, access to clinical and regulatory institutions, and robust digital infrastructure. Importantly, they are doing so with lower attrition, higher workforce stability, and sharper sectoral focus. State governments have accelerated this trend by moving from generic IT policies to GCC-specific blueprints. Telangana, already a recognized tech leader, is seeing growing GCC activity in Warangal, Karimnagar, and Nizamabad, building on Hyderabad's momentum. As per ANSR's Q4'23 GCC report, 3 of 14 new GCCs and 7 of 29 expansions in India occurred in Telangana alone. This momentum is not accidental. With commercial property rates and power tariffs lower than in states like Maharashtra and Karnataka, and a data center pipeline expected to grow from 44 MW in 2023 to 128 MW by 2026, the state is creating the right conditions for digital health operations to flourish. It also helps that Telangana has the highest percentage of employable youth (18–21 years) in India, according to the Wheebox National Employability Test. Andhra Pradesh, too, is moving with intent. The state is positioning Visakhapatnam as a strategic Tier-2 hub for LSHC GCCs by offering rental subsidies of`2,000 per seat for 24 months, power incentives for five years, and housing and education allowances of up to`1 lakh per employee. Combined with an affordable, trained talent pool and a growing appetite for public-private collaboration, AP's model is quietly gaining traction. In Gujarat, the state's life sciences backbone is being augmented with policy muscle. Gujarat's vision includes attracting 250 new GCCs, creating over 50,000 jobs, and securing Rs 10,000 crore in investments. GCCs operating in the state benefit from 100 per cent electricity duty waivers for five years, 80 per cent reimbursement of quality certification fees, and provident fund reimbursements - 100 per cent for female employees and 75 per cent for male employees. For companies operating in regulatory affairs, R&D, and clinical operations, Gujarat offers both capability and continuity. Tamil Nadu is driving a medtech and digital health GCC agenda with Rs 2,295 crore allocated toward expanding operations beyond Chennai. Coimbatore, Madurai, and Trichy are seeing early momentum as the state leverages its industrial legacy, IT base, and deep manufacturing ecosystem to attract global healthcare enterprises. Ongoing investments in IT parks and industrial corridors are reinforcing this long-term intent. Even states that were previously outside the GCC narrative are making credible plays. Uttar Pradesh, for instance, has introduced a targeted GCC policy aimed at channeling investment into Lucknow and Kanpur - home to premier institutions like CDRI and SGPGI. Companies setting up in eligible zones receive land subsidies of up to 50 per cent, 100 per cent stamp duty exemptions, and capital investment subsidies. With foundational infrastructure in place and a large workforce base, UP is building a research-oriented positioning that complements its demographic scale. The corporate response has been pragmatic - and increasingly bold. In Kochi, Aster DM Healthcare's Rs 850 crore investment reflects confidence in Kerala's strategic push toward high-impact healthcare. The Invest Kerala Global Summit has spotlighted Kochi's readiness for innovation-driven GCCs. In Coimbatore, firms are experimenting with digital twin models - simulating drug processes, piloting medtech innovations, and fine-tuning delivery strategies before global rollouts. Vadodara, long a stalwart of the pharmaceutical industry, is attracting attention from global players looking to scale regulatory and analytics capabilities outside saturated metros. And Warangal - powered by its proximity to Hyderabad, NIT-trained talent, and operational setups by LTI Mindtree and Genpact - is becoming a blueprint for how smaller cities can host enterprise-critical operations. 'The attractiveness of Tier-2 cities lies not just in cost arbitrage,' Baliya notes. 'It's in the growing belief that operational excellence and innovation maturity can be achieved outside traditional hubs - with the right partners, policies, and infrastructure.' This shift is more than a footnote in India's GCC evolution. It signals the emergence of a broader, more resilient ecosystem - one that supports diversification, accelerates hiring, and anchors capability where it's most scalable. For global life sciences companies, Tier-2 cities offer a rare trifecta: affordability, depth, and dependability. Importantly, this decentralization aligns closely with India's macroeconomic ambitions. As Telangana and other forward-looking states aspire toward the $1 trillion economy mark, the integration of Tier-2 cities into the global services grid isn't just an operational play - it's a national strategy. It widens the talent funnel, localizes innovation, and deepens India's relevance in global healthcare supply chains. As the healthcare industry becomes more data-intensive, digitally managed, and globally distributed, Tier-2 cities are no longer the second option. They are rising - with intent, with talent, and with a model that fits the future of healthcare delivery. (This article is jointly brought to you by World Trade Center Shamshabad & Future City and Healthark Insights, as part of a knowledge series supporting Telangana's aspiration to become a $1 trillion economy)
